This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

66/100

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Results Among 580 participants (PREVENT-AD, 128; HABS, 153; AIBL, 48; Knight ADRC, 251), mean (SD) age ranged from 67 (5) to 76 (6) years across cohorts, with between 55% (137/251) and 74% (95/128) female participants. Across cohorts, 33% to 83% of A+T+ participants progressed to MCI during follow-up (mean progression time, 2-2.72 years), compared with less than 20% of participants in other biomarker groups.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 580 participants. In older adults without cognitive impairment, those with elevated amyloid and tau PET signal were much more likely to develop mild cognitive impairment within about 2 to 2.7 years than those in other biomarker groups. This suggests these PET scans may help identify people at near-term risk, which could aid prevention trials, but it does not show any treatment works.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Strikwerda-Brown, C., Hobbs, D. A., Gonneaud, J., St-Onge, F., Binette, A. P., Ozlen, H., et al. (2022). Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. JAMA neurology. https://doi.org/10.1001/jamaneurol.2022.2379

Vancouver

Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, et al. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. JAMA neurology. 2022. doi:10.1001/jamaneurol.2022.2379. PMID: 35907254.

BibTeX

@article{strikwerdabrown2022-35907254,
  author  = {Strikwerda-Brown, C. and Hobbs, D. A. and Gonneaud, J. and St-Onge, F. and Binette, A. P. and Ozlen, H. and Provost, K. and Soucy, J. P. and others},
  title   = {{Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2379},
  pmid    = {35907254},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2379}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: this is a follow-up (cohort) study. People are observed over time and not assigned to anything, so an association can reflect other differences between groups. Look at how long follow-up lasted, how many dropped out, and whether the authors adjusted for age, education and other health conditions.
Size: the record lists 580 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded moderate. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Moderate means the abstract mentions a cohort, case-control or longitudinal design. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Results Among 580 participants (PREVENT-AD, 128; HABS, 153; AIBL, 48; Knight ADRC, 251), mean (SD) age ranged from 67 (5) to 76 (6) years across cohorts, with between 55% (137/251) and 74% (95/128) female participants.
Across cohorts, 33% to 83% of A+T+ participants progressed to MCI during follow-up (mean progression time, 2-2.72 years), compared with less than 20% of participants in other biomarker groups.

Why it matters

In older adults without cognitive impairment, those with elevated amyloid and tau PET signal were much more likely to develop mild cognitive impairment within about 2 to 2.7 years than those in other biomarker groups. This suggests these PET scans may help identify people at near-term risk, which could aid prevention trials, but it does not show any treatment works.

New to this subject? Start with our plain-English guide: Brain scans & tests →

Study details

Study designcohort study
Participants580
Evidence strengthModerate

How this study scored 66/100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record	2 / 4	JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2022 — within 6 year(s) of the newest study here
Sample size	2 / 4	580 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 128 times (OpenAlex, 2026-10-10)
Citations per year	4 / 5	21.3 citations a year over 6 year(s) since 2022
Impact for its field and year	4 / 6	Cited 15.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 17 other studies in this library
Still being cited	3 / 4	Cited 94 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Karen Wan: h-index 10 (OpenAlex, whole career)
Institution's track record	2 / 3	Massachusetts General Hospital: institution h-index 2,057 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 15 institution(s) in 5 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 35907254)
Free to read	0 / 2	Behind a paywall — scores zero
Total	66 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Brain scans and imaging from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →